Monograph Capital

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, an important component in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company has a pipeline of next-generation TYK2 inhibitors, which includes a candidate designed to penetrate the brain for the treatment of multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical candidate aimed at addressing immune-mediated dermatologic diseases. Sudo Biosciences aims to provide effective and affordable treatment options for patients suffering from these conditions.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, an important component in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company has a pipeline of next-generation TYK2 inhibitors, which includes a candidate designed to penetrate the brain for the treatment of multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical candidate aimed at addressing immune-mediated dermatologic diseases. Sudo Biosciences aims to provide effective and affordable treatment options for patients suffering from these conditions.

ODAIA is a company that has developed an AI-powered Customer Data Platform specifically for the Life Sciences industry. This innovative platform integrates process mining, customer journey mapping, and artificial intelligence to provide commercial insights and automate processes. By leveraging data analysis, ODAIA's solution enables pharmaceutical commercial teams to enhance personalized selling and ensure that therapeutics reach the patients who require them. The platform aims to streamline decision-making and improve the effectiveness of commercial strategies in the healthcare sector.

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

RegASK Pte. Ltd., founded in 2017 and headquartered in Singapore, is a global RegTech company specializing in regulatory compliance and risk management through an artificial intelligence platform. The company offers a comprehensive range of services, including real-time monitoring of regulatory changes, environmental, social, and governance (ESG) issues management, compliance support, path-to-market and path-to-claim strategies, and product registration for industries such as food, dietary supplements, cosmetics, personal care, and medical devices. By providing instant alerts and insights into regulatory developments, RegASK enables clients to streamline their regulatory research processes, ultimately reducing time and costs while allowing them to concentrate on their core business activities.

Human Immunology Biosciences is a biotechnology company dedicated to developing therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company specializes in precision medicine and focuses on discovering and creating transformative therapies. Its lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has demonstrated the ability to deplete CD38+ cells, including plasma cells and natural killer cells, in clinical studies. This mechanism may enhance clinical outcomes across a range of immune-mediated diseases, offering improved treatment options for patients suffering from these conditions.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.